Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ: ACLX )

90.44 +3.22 (+3.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Analyst Expectations For Arcellx's Future
Via Benzinga
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Navigating 7 Analyst Ratings For Arcellx
Via Benzinga
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
From Arcellx, Inc.
Via Business Wire
Cracking The Code: Understanding Analyst Reviews For Arcellx
Via Benzinga
4 Analysts Assess Arcellx: What You Need To Know
Via Benzinga
Assessing Arcellx: Insights From 7 Financial Analysts
Via Benzinga
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
From Arcellx, Inc.
Via Business Wire
Decoding 8 Analyst Evaluations For Arcellx
Via Benzinga
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
Exposures Product Safety
The Latest Analyst Ratings For Arcellx
Via Benzinga
Expert Ratings For Arcellx
Via Benzinga
Analyst Expectations For Arcellx's Future
Via Benzinga
Arcellx Stock Earns Relative Strength Rating Upgrade
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Arcellx, Inc.
Via Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
Peering Into Arcellx's Recent Short Interest
Via Benzinga
Arcellx Analysts Boost Their Forecasts After Q4 Results
Arcellx, Inc. (NASDAQ: ACLX) posted financial results for its fourth quarter on Wednesday. 
Via Benzinga
Arcellx Provides First Quarter 2024 Financial Results
From Arcellx, Inc.
Via Business Wire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
Arcellx to Participate in Two Upcoming Investor Conferences
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Arcellx, Inc.
Via Business Wire
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
Decoding Bearish Analog And The Warning Signs You Can't Ignore
A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore. 
Via Talk Markets
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.